Dosage and administration
The dug is taken orally.
Chronic cerebral circulatory disorders, vascular cognitive impairment, post-stroke states: 10 mg 3 times/day. The therapeutic effect of the drug is developing gradually and treatment course should be at least 3 months.
Vascular dementia: 30 mg 2 times/day. In this case the patient is recommended every 6 months to consult with your doctor about whether to continue therapy.
Peripheral blood flow disorders: 10 mg 3 times/day for a long time (several months).
Hypersensitivity to nicergoline, heavy bleeding, acute myocardial infarction, orthostatic [postural] hypotension, expressed bradycardia, pregnancy, lactation period, and children under 18 years old.
In very rare cases, clinically irrelevant side effects were noted: Hypotension and dizziness, very slight gastric distress, flushing, sleepiness and insomnia.
Treatment: You should take the horizontal position for a few minutes.
Potentiate action of antihypertensive drugs.
Caution should be used in administering Sermion in patients with hyperuricemia or with a history of gout and/or under treatment with drugs that might be able to interfere with the metabolism and excretion of uric acid. Sermion may potentiate the effect of antihypertensive drugs.
Country of Manufacture: the USA
Nicergoline is an ergot derivative used primarily to treat senile dementia and other disorders which are known to have a vascular origin. It is known to decrease vascular resistance and increase arterial blood flow within the brain, thus improving the utilization of oxygen and glucose uptake by brain cells.
Here you can read more Metabolic Alchemy Review of Sermion
Country of Manufacture: the USA
- Saletu et al (2014) Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163411/
- Winblad et al (2008) Therapeutic use of nicergoline https://www.ncbi.nlm.nih.gov/pubmed/18666801
- M Fioravanti, L Flicker (2001) Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment https://www.ncbi.nlm.nih.gov/pubmed/11687175
- J Kugler, H Heidrich (1984) Nicergoline and cerebral performance insufficiency. Observations in 1 year treatment controls https://www.ncbi.nlm.nih.gov/pubmed/6392047
- Fioravanti et al (2014) A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120366/
- Saletu et al (2014) Safety of nicergoline as an agent for management of cognitive function disorders https://www.ncbi.nlm.nih.gov/pubmed/25243157
- Popova et al (2017) The use nicergoline in the treatment of diabetes mellitus https://www.ncbi.nlm.nih.gov/pubmed/28902812
- Felisati et al (2004) Nicergoline in the treatment of dizziness in elderly patients. A review https://www.ncbi.nlm.nih.gov/pubmed/15207410
- Voronina et al (1988) Effect of nicergoline on learning and memory https://www.ncbi.nlm.nih.gov/pubmed/3419247
- K Shintomi (1991) Pharmacological study of nicergoline. Effects on regional cerebral blood flows and arterial carbon dioxide and oxygen pressure and pH in rats under cyanide-induced histotoxic anoxia https://www.ncbi.nlm.nih.gov/pubmed/1796914
- Nakashima et al (2011) Nicergoline improves dysphagia by upregulating substance P in the elderly https://www.ncbi.nlm.nih.gov/pubmed/21694649
- Dikova et al (1990) Rheoencephalographic and electroencephalographic studies on nicergoline https://www.ncbi.nlm.nih.gov/pubmed/2232965
- Walford et al (2016) Nicergoline inhibits human platelet Ca2+signalling through triggering a microtubule‐dependent reorganization of the platelet ultrastructure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813371/
- Bottiger et al (1996) Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans https://www.ncbi.nlm.nih.gov/pubmed/8971425
- Mizuno et al (2005) Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes https://www.ncbi.nlm.nih.gov/pubmed/16325157